| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Cavutilide targets the hERG (human Ether-à-go-go-Related Gene) K+ channel. By inhibiting this channel, the compound prolongs the cardiac action potential duration, which can suppress arrhythmias. This mechanism is characteristic of class III antiarrhythmic agents. The compound is being studied for the treatment of persistent atrial fibrillation.
|
|---|---|
| ln Vitro |
In vitro, Cavutilide inhibits hERG K+ channel activity. Specific IC50 values for hERG channel inhibition are not provided in the available sources. Its activity is characterized in electrophysiological assays measuring potassium currents in cells expressing hERG channels.
|
| ln Vivo |
In vivo, Cavutilide has antiarrhythmic activity. It is being studied for the treatment of heart failure and persistent atrial fibrillation. Specific in vivo efficacy data, such as effects on arrhythmia burden in animal models, are not provided in the available sources.
|
| Enzyme Assay |
A cell-free assay for Cavutilide would involve measuring its inhibition of hERG channel activity using patch-clamp techniques on isolated hERG channels expressed in heterologous systems. The compound's ability to block potassium currents through the hERG channel would be assessed. Specific IC50 values are not provided.
|
| Cell Assay |
Cellular assays for Cavutilide typically involve measuring its effects on hERG channel activity using patch-clamp electrophysiology on cells expressing hERG channels. Cells are treated with the compound, and the inhibition of hERG-mediated potassium currents is measured. Specific protocols are not detailed.
|
| Animal Protocol |
In vivo animal experiments for Cavutilide are not described in the available sources. As an antiarrhythmic agent, it could be evaluated in animal models of atrial fibrillation or heart failure. However, no specific protocols or data are provided.
|
| ADME/Pharmacokinetics |
Cavutilide has a molecular formula of C22H26FN3O3 and a molecular weight of 399.46. It is a benzamide derivative. Specific pharmacokinetic parameters, such as half-life and bioavailability, are not provided in the available sources. The compound is being studied for its antiarrhythmic potential.
|
| Toxicity/Toxicokinetics |
Toxicity data for Cavutilide are not provided in the available sources. As a research compound, it is intended for research use only and not for human consumption. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
Cavutilide (CAS: 1276186-19-6) is a class III antiarrhythmic agent that inhibits the hERG K+ channel. It is also known as Niferidil. The compound has antiarrhythmic activity and can be used to study heart failure and persistent atrial fibrillation. Its molecular formula is C22H26FN3O3 and its molecular weight is 399.46. It is not an approved drug and is strictly for research purposes.
|
| Molecular Formula |
C22H26FN3O3
|
|---|---|
| Molecular Weight |
399.458549022675
|
| CAS # |
1276186-19-6
|
| Related CAS # |
1276021-10-3 (HCl);1276186-19-6;
|
| PubChem CID |
57331232
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
532
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NC(C1=CC=C(F)C=C1)CC2CCN(CC)CC2)C3=CC=C([N+]([O-])=O)C=C3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5034 mL | 12.5169 mL | 25.0338 mL | |
| 5 mM | 0.5007 mL | 2.5034 mL | 5.0068 mL | |
| 10 mM | 0.2503 mL | 1.2517 mL | 2.5034 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
